The road ahead

The connection between HPV and oral cancer is becoming clearer. Some population types and risk factors have become closely linked to HPV-associated OSCC. The relationship between HPV-associated OSCC and certain lifestyle practices has also been identified. New methods of detecting HPV (including subtypes) in the oral cavity will become more important to the development of treatment protocols. Finally, the impact of vaccines on the prevalence of oral cancer is currently undefined but presents exciting possibilities. n

Dr. Weiss is an oral & maxillofacial surgery resident, and Dr. Dym is Chairman, Department of Dentistry and Oral & Maxillofacial Surgery, at The Brooklyn Hospital Center in Brooklyn, N.Y. The authors have no relationships to disclose relating to the content of this article.

HOW TO TAKE THE POST-TEST: To obtain CME/CE credit, please click here after reading the article to take the post-test on


1. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527.

2. Silverman S, Eversole LR, Truelove EL. Essentials of Oral Medicine. Hamilton, Ontario: BC Decker, Inc.; 2002:144-151.

3. Greer RO, Goldman HM. Oral papillomas. Clinicopathologic evaluation and retrospective examination for dyskeratosis in 110 lesions. Oral Surg Oral Med Oral Pathol. 1974;38:435-440.

4. Marx RE, Stern D. Oral and Maxillofacial Pathology: A Rationale for Treatment. Hanover Park, Ill.: Quintessence Publishing; 2003:page.

5. Syrjänen K, Syrjänen S, Lamberg M, et al. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg. 1983;12:418-424.

6. Walboomers JM, Jacobs MV, Manos MM, et al. Human papilloma­virus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.

7. Soames JV, Southam JC. Oral Pathology. New York, N.Y.: Oxford University Press; 2005:138.

8. Gillison ML, Shah KV. Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol. 2001;13:183-188.

9. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14:467-475.

10. Rosenquist K, Wennerberg J, Schildt EB, et al. Oral status, oral infections and some lifestyle factors as risk factors for oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden. Acta Otolaryngol. 2005;125:1327-1336.

11. Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91:622-635.

12. Dhar PK, Rao TR, Sreekumaran Nair N, et al. Identification of risk factors for specific subsites within the oral and oropharyngeal region—a study of 647 cancer patients. Indian J Cancer. 2000;37:114-122.

13. Sankaranarayanan R, Duffy SW, Padmakumary G, et al. Risk factors for cancer of the buccal and labial mucosa in Kerala, southern India. J Epidemiol Community Health. 1990;44:286-292.

14. Gillison ML, Shah KV. Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol. 2001;13:183-188.

15. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer. 2005;103:1843-1849.

16. Gillison ML. Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: implications for clinical research in head and neck cancers. J Clin Oncol. 2006 Dec 20;24(36):5623-5.

17. Lindel K, Beer KT, Laissue J, et al. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer. 2001;92:805-813.

18. Cruz IB, Snijders PJ, Steenbergen RD, et al. Age-dependence of human papillomavirus DNA presence in oral squamous cell carcinomas. Eur J Cancer B Oral Oncol. 1996;32B:55-62.

19. Ringström E, Peters E, Hasegawa M, et al. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res. 2002;8:3187-3192. 

20. Gillison ML, D’Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100:407-420.

21. Adamopoulou M, Vairaktaris E, Panis V, et al. HPV detection rate in saliva may depend on the immune system efficiency. In Vivo. 2008;22:599-602.

22. Völter C, He Y, Delius H, et al. Novel HPV types present in oral papillomatous lesions from patients with HIV infection. Int J Cancer. 1996;66:453-456.

23. Greenspan D, Canchola AJ, MacPhail LA, et al. Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet. 2001;357:1411-1412.

24. King MD, Reznik DA, O’Daniels CM, et al. Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis. 2002;34:641-648.

25. Boyle FM, Dunne MP, Purdie DM, et al. Early patterns of sexual activity: age cohort differences in Australia. Int J STD AIDS. 2003;14:745-752.

26. D’Souza G, Agrawal Y, Halpern J, et al. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis.2009;199:1263-1269.

27. D’Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. NEJM. 2007;356:1944-1956. http:///

28. Herrero R, Castellsagué X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003;95:1772-1783. 

29. Schwartz SR, Yueh B, McDougall JK, et al. Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg. 2001;125:1-9.

30. Butz K, Geisen C, Ullmann A, et al. Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis. Int J Cancer. 1996;68:506-513.

31. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol. 2004;31:744-754.

32. Agrawal Y, Koch WM, Xiao W, et al. Oral human papillomavirus infection before and after treatment for human papillomavirus 16-positive and human papillomavirus 16-negative head and neck squamous cell carcinoma. Clin Cancer Res. 2008;14:7143-7150.

33. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-1255.

HOW TO TAKE THE POST-TEST: To obtain CME/CE credit, please click here after reading the article to take the post-test on